Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: Pooled analysis of data from five clinical trials
Clinical Rheumatology, 06/24/09
Choy EHS et al. - Data summarizes the short- and long-term safety from five clinical studies in patients treated with duloxetine for fibromyalgia. In addition, postmarketing surveillance continues for adverse events reported with duloxetine in fibromyalgia, as in other indications.
Methods- Study describes the overall safety profile of both short- and longer-term duloxetine treatment of fibromyalgia
- Data from 4 studies: 2 with 6-mo open-label extension phases and a 1-yr, open-label safety study
- Safety measures included:
- Treatment-emergent adverse events (TEAEs)
- Adverse events leading to discontinuation
- Serious adverse events (SAEs)
- Clinical laboratory tests, vital signs, and electrocardiograms
- Most common TEAEs for short-term treatment: nausea, headache, dry mouth, insomnia, fatigue, constipation, diarrhea, and dizziness
- Most TEAEs emerged early and were mild to moderate in severity
- Profile of AEs in pts enrolled at least 6 mo, and in the 1-yr study, was similar to that found in the short-term treatment studies
- 20% of pts discontinued due to AEs in short-term treatment studies and in 1-yr study
- SAEs were uncommon, and none occurred at a higher frequency vs placebo
- Mean changes in vital signs and weight were small
- Rates of treatment-emergent potentially clinically significant (PCS) vital sign, laboratory, and electrocardiogram measures were low
- Only PCS rates of alanine aminotransferase were higher for duloxetine vs placebo
- In the 1-yr study, 4 pts (1.1%) had suicide-related behavior
Today in Chr Fatigue/Fibromyalgia...keeping you current
Receive free subspecialty "5-minute updates" via email
What Makes Patients with Fibromyalgia Feel Better? Correlations Between Patient Global Impression of Improvement and Changes in Clinical Symptoms and Function: A Pooled Analysis of 4 Randomized Placebo-controlled Trials of Duloxetine
Journal of Rheumatology, 10/16/09
Traditional Chinese medicinal herbs for the treatment of idiopathic chronic fatigue and chronic fatigue syndrome
Cochrane Reviews, 10/12/09
Fibromyalgia and Myofascial Pain Syndrome - A Dilemma
Indian Journal of Anaesthesia, 10/22/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Sponsor
Article Search
Sponsor


See Latest Articles


